• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

JAMA Netw Open . Cognitive Rehabilitation and Functional Outcomes in Long COVID-Related Cognitive Impairment: A Randomized Clinical Trial

tetano

Editor, Senior Moderator
JAMA Netw Open


. 2026 Jul 1;9(7):e2620687.
doi: 10.1001/jamanetworkopen.2026.20687.
Cognitive Rehabilitation and Functional Outcomes in Long COVID-Related Cognitive Impairment: A Randomized Clinical Trial

Martina Vanova[SUP] 1 2 [/SUP], Aysha Mohamed Rafik Patel[SUP] 3 [/SUP], Iona Scott[SUP] 3 [/SUP], Gina Gilpin[SUP] 3 [/SUP], Emily N Manning[SUP] 3 [/SUP], Charlotte Ash[SUP] 3 [/SUP], Philippa Wittenberg[SUP] 3 [/SUP], Jason Lim[SUP] 4 [/SUP], Zoe Hoare[SUP] 5 [/SUP], Rachel Evans[SUP] 5 [/SUP], Nathan Bray[SUP] 6 [/SUP], Christopher M Kipps[SUP] 7 [/SUP], Ciara Devine[SUP] 7 [/SUP], Saliha Ahmed[SUP] 8 [/SUP], Ross Dunne[SUP] 8 9 [/SUP], Anna Koniotes[SUP] 10 [/SUP], Catherine Warren[SUP] 10 [/SUP], Dennis Chan[SUP] 3 10 [/SUP], Aida Suarez-Gonzalez[SUP] 1 [/SUP]


Affiliations
Abstract

Importance: Cognitive impairment is common in long COVID and severely affects daily life, with no proven treatments to date.
Objective: To evaluate the ability of cognitive rehabilitation (CR) to improve goal attainment, cognitive, and clinical outcomes in individuals with cognitive impairment as part of long COVID.
Design, setting, and participants: This multicenter, single-blind, 2-arm, parallel-group randomized clinical trial was conducted at 3 sites in England between February 2023 and March 2024. Participants were adults aged 30 to 60 years with prior COVID-19 infection and objective cognitive impairment (≥1 SD below age norm in ≥2 cognitive domains). A sample size of 88 participants (44:44) was required to detect a conservative effect of 0.7 on the goal attainment score at 3 months.
Interventions: Participants were randomized (1:1) to CR or treatment as usual (TAU). CR consisted of 10 individual 1-hour sessions conducted once per week with a trained researcher, applying evidence-based strategies to 3 individually selected, personally meaningful functional goals. TAU was variable, with most participants having access to specialist memory clinics.
Main outcome and measures: The primary outcome consisted of participant-reported goal-attainment scores at 3 months after randomization measured by the Bangor Goal-Setting Interview. Analysis was conducted on an intention-to-treat basis using multilevel mixed-effects models with 2-sided 95% CIs and 5% significance.
Results: A total of 78 participants (24 male [30.8%] and 54 female [69.2%]; mean [SD] age, 47.3 [7.2] years) were randomized, including 38 individuals in CR and 40 individuals in TAU groups. At 3 months after randomization, goal attainment was significantly greater in the CR compared with the TAU group (adjusted mean difference, 2.88 [95% CI, 2.03-3.73]; P < .001; Cohen d = 1.57), with CR providing a large and clinically meaningful treatment effect. This was sustained at 6 months, with a lower effect size (adjusted mean difference, 1.72 [95% CI, 0.86-2.57]; P < .001; Cohen d = 0.91).
Conclusions and relevance: In this study, individualized, goal-oriented CR led to significant and sustained improvements in goal attainment in people with long COVID-related cognitive impairment. These findings may guide and inform the provision of CR treatments and services for people living with long COVID.
Trial registration: ClinicalTrials.gov Identifier: NCT05731570.


 
Back
Top